Use of antisense oligonucleotides to target Notch3 in skeletal cells.
Use of antisense oligonucleotides to target Notch3 in skeletal cells.
复制标题
DOI：
10.1371/journal.pone.0268225
复制
发表时间：
2022
期刊：
影响因子：
3.7
通讯作者：
中科院分区：
文献类型：
--
作者：
Notch receptors are determinants of cell fate and function, and play an important role in the regulation of bone development and skeletal remodeling. Lateral Meningocele Syndrome (LMS) is a monogenic disorder associated with NOTCH3 pathogenic variants that result in the stabilization of NOTCH3 and a gain-of-function. LMS presents with neurological developmental abnormalities and bone loss. We created a mouse model (Notch3em1Ecan) harboring a 6691TAATGA mutation in the Notch3 locus, and heterozygous Notch3em1Ecan mice exhibit cancellous and cortical bone osteopenia. In the present work, we explored whether Notch3 antisense oligonucleotides (ASO) downregulate Notch3 and have the potential to ameliorate the osteopenia of Notch3em1Ecan mice. Notch3 ASOs decreased the expression of Notch3 wild type and Notch36691-TAATGA mutant mRNA expressed by Notch3em1Ecan mice in osteoblast cultures without evidence of cellular toxicity. The effect was specific since ASOs did not downregulate Notch1, Notch2 or Notch4. The expression of Notch3 wild type and Notch36691-TAATGA mutant transcripts also was decreased in bone marrow stromal cells and osteocytes following exposure to Notch3 ASOs. In vivo, the subcutaneous administration of Notch3 ASOs at 25 to 50 mg/Kg decreased Notch3 mRNA in the liver, heart and bone. Microcomputed tomography demonstrated that the administration of Notch3 ASOs ameliorates the cortical osteopenia of Notch3em1Ecan mice, and ASOs decreased femoral cortical porosity and increased cortical thickness and bone volume. However, the administration of Notch3 ASOs did not ameliorate the cancellous bone osteopenia of Notchem1Ecan mice. In conclusion, Notch3 ASOs downregulate Notch3 expression in skeletal cells and their systemic administration ameliorates cortical osteopenia in Notch3em1Ecan mice; as such ASOs may become useful strategies in the management of skeletal diseases affected by Notch gain-of-function.
登录
查看更多内容
影响因子：
9.8
作者：
Filipowska J;Tomaszewski KA;Niedźwiedzki Ł;Walocha JA;Niedźwiedzki T
通讯作者：
Niedźwiedzki T
DOI：
10.1002/ajmg.a.36863
发表时间：
2015-03
期刊：
American journal of medical genetics. Part A
影响因子：
--
作者：
Gripp KW;Robbins KM;Sobreira NL;Witmer PD;Bird LM;Avela K;Makitie O;Alves D;Hogue JS;Zackai EH;Doheny KF;Stabley DL;Sol-Church K
通讯作者：
Sol-Church K
DOI：
10.1016/j.jbc.2021.100583
发表时间：
2021-01
期刊：
The Journal of biological chemistry
影响因子：
--
作者：
Canalis E;Zanotti S;Schilling L;Eller T;Yu J
通讯作者：
Yu J
影响因子：
48
作者：
Gibson, Daniel G.;Young, Lei;Smith, Hamilton O.
通讯作者：
Smith, Hamilton O.
骨骼生理和疾病的缺口。
DOI：
10.1007/s00198-018-4694-3
发表时间：
2018-12
期刊：
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
影响因子：
--
作者：
Canalis E
通讯作者：
Canalis E